S. Décalage, injection : deux types de non-observance ?, p.51

V. , A. Loftus, E. , J. Colombel, J. Sandborn et al., The natural history of adult Crohn's disease in population-based cohorts, Am J Gastroenterol, vol.105, pp.289-97, 2009.

G. Van-assche, S. Vermeire, and P. Rutgeerts, The potential for disease modification in Crohn's disease, Nature Reviews Gastroenterology & Hepatology, vol.135, issue.2, pp.79-85, 2010.
DOI : 10.1016/S0016-5085(04)02215-2

R. Haynes, Determinants of compliance: The disease and the mechanics of treatment

C. Rand, Measuring adherence with therapy for chronic diseases: Implications for the treatment of heterozygous familial hypercholesterolemia, The American Journal of Cardiology, vol.72, issue.10, pp.68-74, 1993.
DOI : 10.1016/0002-9149(93)90014-4

S. Kane, R. Cohen, J. Aikens, and S. Hanauer, Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis, The American Journal of Gastroenterology, vol.8, issue.10, pp.2929-2962, 2001.
DOI : 10.1046/j.1365-2036.2000.00698.x

E. Loftus and J. , A practical perspective on ulcerative colitis: Patients?? needs from aminosalicylate therapies, Inflammatory Bowel Diseases, vol.18, issue.12, pp.1107-1120, 2006.
DOI : 10.1046/j.1365-2036.2003.01648.x

G. Moody, V. Jayanthi, C. Probert, M. Kay, H. Mayberry et al., Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire, European Journal of Gastroenterology & Hepatology, vol.8, issue.12, pp.1179-83, 1996.
DOI : 10.1097/00042737-199612000-00009

M. Shale and S. Riley, Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease Compliance to therapy in patients on a maintenance dose of sulfasalazine, Aliment Pharmacol Ther J Clin Gastroenterol, vol.184, pp.191-8333, 1982.

R. Bloomfeld and J. Onken, Mercaptopurine metabolite results in clinical gastroenterology practice, Alimentary Pharmacology and Therapeutics, vol.118, issue.1, pp.69-73, 2003.
DOI : 10.1016/S0016-5085(00)70354-4

URL : http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2003.01392.x/pdf

G. Mantzaris, A. Roussos, C. Kalantzis, S. Koilakou, N. Raptis et al., How Adherent to Treatment With Azathioprine Are Patients With Crohn??s Disease in Long-term Remission?, Inflammatory Bowel Diseases, vol.305, issue.6844, pp.446-50, 2007.
DOI : 10.1046/j.1365-2036.2003.01392.x

S. Wright, D. Sanders, A. Lobo, and L. Lennard, Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease, Gut, vol.53, issue.8, pp.1123-1131, 2004.
DOI : 10.1136/gut.2003.032896

S. Kane and F. Shaya, Medication Non-adherence is Associated with Increased Medical Health Care Costs, Digestive Diseases and Sciences, vol.31, issue.11, pp.1020-1024, 2008.
DOI : 10.1007/s10620-007-9968-0

S. Kane, J. Chao, and P. Mulani, Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn???s disease patients, Advances in Therapy, vol.11, issue.suppl.1, pp.936-982, 2009.
DOI : 10.1111/j.1524-4733.2007.00213.x

S. Kane, D. Huo, J. Aikens, and S. Hanauer, Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis, The American Journal of Medicine, vol.114, issue.1, pp.39-43, 2003.
DOI : 10.1016/S0002-9343(02)01383-9

J. Colombel, W. Sandborn, P. Rutgeerts, R. Enns, S. Hanauer et al., Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn???s Disease: The CHARM Trial, Gastroenterology, vol.132, issue.1
DOI : 10.1053/j.gastro.2006.11.041

S. Hanauer, B. Feagan, G. Lichtenstein, L. Mayer, S. Schreiber et al., Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, The Lancet, vol.359, issue.9317, pp.1541-1550, 2002.
DOI : 10.1016/S0140-6736(02)08512-4

S. Schreiber, M. Khaliq-kareemi, I. Lawrance, O. Thomsen, S. Hanauer et al., Maintenance Therapy with Certolizumab Pegol for Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.239-50, 2007.
DOI : 10.1056/NEJMoa062897

L. Peyrin-biroulet, . Dp, C. Stalgis, W. Sandborn, and J. Colombel, Achieving long-term maintenance of remission in Crohn's disease: are all anti-TNF created equal ?, Gut, vol.55, p.131, 2006.

S. Kane and L. Dixon, Adherence rates with infliximab therapy in Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.4, issue.7, pp.1099-103, 2006.
DOI : 10.1053/cgh.2003.50025

J. Ediger, J. Walker, L. Graff, L. Lix, C. I. Rawsthorne et al., Predictors of Medication Adherence in Inflammatory Bowel Disease, The American Journal of Gastroenterology, vol.54, issue.7, pp.1417-1443, 2007.
DOI : 10.1097/01.mlr.0000114908.90348.f9

P. Cerveny, M. Bortlik, A. Kubena, J. Vlcek, P. Lakatos et al., Nonadherence in inflammatory bowel disease: Results of factor analysis, Inflammatory Bowel Diseases, vol.1119, issue.10, pp.1244-1253, 2007.
DOI : 10.1016/j.chroma.2006.01.058

D. Inca, R. Bertomoro, P. Mazzocco, K. Vettorato, M. Rumiati et al., Risk factors for non-adherence to medication in inflammatory bowel disease patients

G. Nguyen, T. Laveist, M. Harris, L. Datta, T. Bayless et al., Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease, Inflammatory Bowel Diseases, vol.24, issue.8, pp.1233-1242, 2009.
DOI : 10.1097/00005650-198601000-00007

A. Lopez-san-roman, F. Bermejo, E. Carrera, M. Perez-abad, and D. Boixeda, Adherence to treatment in inflammatory bowel disease, Revista Espa??ola de Enfermedades Digestivas, vol.97, issue.4, pp.249-57, 2005.
DOI : 10.4321/S1130-01082005000400005

I. Bernal, E. Domenech, E. Garcia-planella, L. Marin, M. Manosa et al., Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease, Digestive Diseases and Sciences, vol.5, issue.12, pp.2165-2174, 2006.
DOI : 10.1007/s10620-006-9444-2

R. Horne, R. Parham, R. Driscoll, and A. Robinson, Patients?? attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease, Inflammatory Bowel Diseases, vol.64, issue.6, pp.837-881, 2009.
DOI : 10.1111/j.1365-2036.2006.02809.x

G. Nigro, G. Angelini, S. Grosso, G. Caula, and C. Sategna-guidetti, Psychiatric Predictors of Noncompliance in Inflammatory Bowel Disease, Journal of Clinical Gastroenterology, vol.32, issue.1, pp.66-74, 2001.
DOI : 10.1097/00004836-200101000-00015

M. Sewitch, K. Leffondre, and P. Dobkin, Clustering patients according to health perceptions, Journal of Psychosomatic Research, vol.56, issue.3, pp.323-355, 2004.
DOI : 10.1016/S0022-3999(03)00508-7

R. Mcleod, B. Wolff, S. Ross, R. Parkes, and M. Mckenzie, Recurrence of Crohn's Disease After Ileocolic Resection Is Not Affected by Anastomotic Type, Diseases of the Colon & Rectum, vol.52, issue.5, pp.919-946, 2009.
DOI : 10.1007/DCR.0b013e3181a4fa58

S. Targan, S. Hanauer, S. Van-deventer, L. Mayer, D. Present et al., A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor ?? for Crohn's Disease, New England Journal of Medicine, vol.337, issue.15, pp.1029-1064, 1997.
DOI : 10.1056/NEJM199710093371502

W. Sandborn, S. Hanauer, E. Loftus, J. Tremaine, W. Kane et al., An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease, The American Journal of Gastroenterology, vol.52, issue.10, pp.1984-1993, 2004.
DOI : 10.1053/gast.2003.50182

S. Hanauer, W. Sandborn, P. Rutgeerts, R. Fedorak, M. Lukas et al., Human Anti???Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn???s Disease: the CLASSIC-I Trial, Gastroenterology, vol.130, issue.2, pp.323-356, 2006.
DOI : 10.1053/j.gastro.2005.11.030

W. Sandborn, P. Rutgeerts, R. Enns, S. Hanauer, J. Colombel et al., Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab, Annals of Internal Medicine, vol.146, issue.12, pp.829-867, 2007.
DOI : 10.7326/0003-4819-146-12-200706190-00159

W. Sandborn, B. Feagan, S. Stoinov, P. Honiball, P. Rutgeerts et al., Certolizumab Pegol for the Treatment of Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.228-266, 2007.
DOI : 10.1056/NEJMoa067594

P. Allen, H. Lindsay, and T. Tham, How do patients with inflammatory bowel disease want their biological therapy administered?, BMC Gastroenterology, vol.30, issue.3, 2010.
DOI : 10.1111/j.1365-2036.2009.04033.x

URL : https://doi.org/10.1186/1471-230x-10-1

F. Chilton and R. Collett, Treatment choices, preferences and decision-making by patients with rheumatoid arthritis, Musculoskeletal Care, vol.6, issue.1, pp.1-14, 2008.
DOI : 10.7861/clinmedicine.6-1-105

S. Scarpato, M. Antivalle, E. Favalli, F. Nacci, S. Frigelli et al., Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study), Rheumatology, vol.55, issue.6, pp.289-94, 2009.
DOI : 10.1002/art.22355

A. Yu, S. Johnson, S. Wang, P. Atanasov, J. Tang et al., Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn??s Disease, PharmacoEconomics, vol.13, issue.6, pp.609-630, 2009.
DOI : 10.2165/11312710-000000000-00000

G. Kaplan, C. Hur, J. Korzenik, and B. Sands, Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn???s disease: a cost-effectiveness analysis, Alimentary Pharmacology & Therapeutics, vol.56, issue.11-12
DOI : 10.1177/027298902320556118

A. Cassinotti and S. Travis, Incidence and clinical significance of immunogenicity to infliximab in Crohn??s disease, Inflammatory Bowel Diseases, vol.26, issue.8, pp.1264-75, 2009.
DOI : 10.1053/j.gastro.2006.02.038

W. Sandborn, S. Hanauer, P. Rutgeerts, R. Fedorak, M. Lukas et al., Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial, Gut, vol.56, issue.9, pp.1232-1241, 2007.
DOI : 10.1136/gut.2006.106781

B. Yamout, M. Dahdaleh, A. Jumah, M. Shammri, S. et al., Adherence to Disease-Modifying Drugs in Patients with Multiple Sclerosis: A Consensus Statement from the Middle East MS Advisory Group, International Journal of Neuroscience, vol.76, issue.1, pp.273-282, 2010.
DOI : 10.1212/01.WNL.0000078885.05053.7D

J. Mchutchison, M. Manns, K. Patel, T. Poynard, K. Lindsay et al., Adherence to combination therapy enhances sustained response in genotype-1???infected patients with chronic hepatitis C, Gastroenterology, vol.123, issue.4
DOI : 10.1053/gast.2002.35950

P. Cacoub, D. Ouzan, P. Melin, J. Lang, M. Rotily et al., Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A prospective, real-life, observational study, World Journal of Gastroenterology, vol.14, issue.40, pp.6195-203, 2008.
DOI : 10.3748/wjg.14.6195

J. Weiss, L. Bhatti, D. Dieterich, B. Edlin, D. Fishbein et al., Hepatitis C patients??? self-reported adherence to treatment with pegylated interferon and ribavirin, Alimentary Pharmacology & Therapeutics, vol.17, issue.Suppl. 3, pp.289-93, 2008.
DOI : 10.1097/00126334-200104150-00005

P. Nicoletta, J. Bernardini, C. Dacko, C. Terry, and L. Fried, Compliance with subcutaneous erythropoietin in peritoneal dialysis patients, Adv Perit Dial, vol.16, pp.90-92, 2000.

J. Adachi, D. Hanley, J. Lorraine, and M. Yu, Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study, Clinical Therapeutics, vol.29, issue.9, pp.2055-67, 2007.
DOI : 10.1016/j.clinthera.2007.09.024

F. Nunez, G. Diaz-cordoves, M. Lopez-lasanta, A. Ponce, M. Rodriguez-perez et al., Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis, J Rheumatol, vol.34, pp.2334-2376, 2007.

S. Curkendall, V. Patel, M. Gleeson, R. Campbell, M. Zagari et al., Compliance with biologic therapies for rheumatoid arthritis: Do patient out-of-pocket payments matter?, Arthritis & Rheumatism, vol.354, issue.10, pp.1519-1545, 2008.
DOI : 10.1002/art.24114

B. Borah, X. Huang, V. Zarotsky, and D. Globe, Trends in RA patients??? adherence to subcutaneous anti-TNF therapies and costs, Current Medical Research and Opinion, vol.25, issue.6, p.8, 2009.
DOI : 10.1185/03007990902896386

M. Hetland, I. Christensen, U. Tarp, L. Dreyer, A. Hansen et al., Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry, Arthritis & Rheumatism, vol.64, issue.5, pp.22-32, 2010.
DOI : 10.7326/0003-4819-148-2-200801150-00192

S. Kane, Systematic review: adherence issues in the treatment of ulcerative colitis, Alimentary Pharmacology and Therapeutics, vol.100, issue.1
DOI : 10.2165/00126839-200506010-00005

J. Satsangi, M. Silverberg, S. Vermeire, and J. Colombel, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006.
DOI : 10.1136/gut.2005.082909

G. Plosker and K. Lyseng-williamson, Adalimumab, BioDrugs, vol.20, issue.5, pp.125-157, 2007.
DOI : 10.2165/00063030-200721020-00007

T. Moshkovska, M. Stone, R. Baker, and J. Mayberry, Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, Inflammatory Bowel Diseases, vol.65, issue.6, pp.763-771, 2008.
DOI : 10.1016/j.pec.2006.09.012

A. Christensen, L. Christrup, P. Fabricius, M. Chrostowska, M. Wronka et al., The impact of an electronic monitoring and reminder device on patient compliance with antihypertensive therapy: a randomized controlled trial, Journal of Hypertension, vol.28, issue.1, pp.194-200, 2010.
DOI : 10.1097/HJH.0b013e328331b718

U. Strandbygaard, S. Thomsen, and V. Backer, A daily SMS reminder increases adherence to asthma treatment: A three-month follow-up study, Respiratory Medicine, vol.104, issue.2, pp.166-71, 2009.
DOI : 10.1016/j.rmed.2009.10.003

A. Kivitz, S. Cohen, J. Dowd, W. Edwards, S. Thakker et al., Clinical Assessment of Pain, Tolerability, and Preference of an Autoinjection Pen Versus a Prefilled Syringe for Patient Self-Administration of the Fully Human, Monoclonal Antibody Adalimumab: The TOUCH Trial, Clinical Therapeutics, vol.28, issue.10, pp.1619-1648, 2006.
DOI : 10.1016/j.clinthera.2006.10.006

J. Borras-blasco, A. Gracia-perez, J. Rosique-robles, M. Castera, and F. Abad, Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen, Expert Opinion on Biological Therapy, vol.56, issue.2, pp.301-308, 2010.
DOI : 10.1093/rheumatology/kel369

A. Laboratories, HUMIRA® (adalimumab) [en ligne]: www.rxabbott.com/pdf/humira, 2010.

N. Kerse, S. Buetow, A. Mainous, G. Young, G. Coster et al., Physician-Patient Relationship and Medication Compliance: A Primary Care Investigation, The Annals of Family Medicine, vol.2, issue.5, pp.455-61, 2004.
DOI : 10.1370/afm.139

A. Hawthorne, G. Rubin, and S. Ghosh, Review article: medication non-adherence in ulcerative colitis - strategies to improve adherence with mesalazine and other maintenance therapies, Alimentary Pharmacology & Therapeutics, vol.20, issue.Suppl. 1, pp.1157-66, 2008.
DOI : 10.1155/2005/250504

K. Krueger, B. Felkey, and B. Berger, Improving Adherence Persistence: A Review Assessment of Interventions Description of Steps Toward a National Adherence Initiative, Journal of the American Pharmacists Association, vol.43, issue.6, pp.668-78, 2003.
DOI : 10.1331/154434503322642598

B. Waters, L. Jensen, and R. Fedorak, Effects of Formal Education for Patients with Inflammatory Bowel Disease: A Randomized Controlled Trial, Canadian Journal of Gastroenterology, vol.19, issue.4, pp.235-279, 2005.
DOI : 10.1155/2005/250504

R. Hansen, M. Kim, L. Song, W. Tu, J. Wu et al., Adherence: Comparison of Methods to Assess Medication Adherence and Classify Nonadherence, Annals of Pharmacotherapy, vol.43, issue.3, pp.413-435, 2009.
DOI : 10.1177/096228020000900304

R. Horne and J. Weinman, Self-regulation and Self-management in Asthma: Exploring The Role of Illness Perceptions and Treatment Beliefs in Explaining Non-adherence to Preventer Medication, Psychology & Health, vol.149, issue.1, pp.17-32, 2002.
DOI : 10.1080/08870449608400270

M. Kim, M. Hill, L. Bone, and D. Levine, Development and Testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale, Progress in Cardiovascular Nursing, vol.82, issue.3, pp.90-96, 2000.
DOI : 10.1093/ajh/1.3.192S

D. Morisky, L. Green, and D. Levine, Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence, Medical Care, vol.24, issue.1, pp.67-74, 1986.
DOI : 10.1097/00005650-198601000-00007

L. Osterberg and T. Blaschke, Adherence to Medication, New England Journal of Medicine, vol.353, issue.5, pp.487-97, 2005.
DOI : 10.1056/NEJMra050100

V. Peyrin-biroulet, L. Loftus, E. , J. Colombel, and J. , The Natural History of Adult Crohn's Disease in Population-Based Cohorts, The American Journal of Gastroenterology, vol.132, issue.2, pp.289-97, 2009.
DOI : 10.1053/j.gastro.2008.09.053

G. Van-assche, S. Vermeire, and P. Rutgeerts, The potential for disease modification in Crohn's disease, Nature Reviews Gastroenterology & Hepatology, vol.135, issue.2, pp.79-85
DOI : 10.1016/S0016-5085(04)02215-2

S. Kane, R. Cohen, and J. Aikens, Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis, The American Journal of Gastroenterology, vol.8, issue.10, pp.2929-2962, 2001.
DOI : 10.1046/j.1365-2036.2000.00698.x

E. Loftus and J. , A practical perspective on ulcerative colitis: Patients?? needs from aminosalicylate therapies, Inflammatory Bowel Diseases, vol.18, issue.12, pp.1107-1120, 2006.
DOI : 10.1046/j.1365-2036.2003.01648.x

G. Moody, V. Jayanthi, and C. Probert, Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire, European Journal of Gastroenterology & Hepatology, vol.8, issue.12, pp.1179-83, 1996.
DOI : 10.1097/00042737-199612000-00009

M. Shale and S. Riley, Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease Compliance to therapy in patients on a maintenance dose of sulfasalazine, Aliment Pharmacol Ther J Clin Gastroenterol, vol.184, pp.191-8333, 1982.

R. Bloomfeld and J. Onken, Mercaptopurine metabolite results in clinical gastroenterology practice, Alimentary Pharmacology and Therapeutics, vol.118, issue.1, pp.69-73, 2003.
DOI : 10.1016/S0016-5085(00)70354-4

B. Bokemeyer, A. Teml, and C. Roggel, Adherence to thiopurine treatment in out-patients with Crohn??????s disease, Alimentary Pharmacology & Therapeutics, vol.348, issue.Suppl. 1, pp.217-242, 2007.
DOI : 10.1097/01.qai.0000248346.79888.78

G. Mantzaris, A. Roussos, and C. Kalantzis, How adherent to treatment with azathioprine Page, p.24

J. Wiley, &. Wright, S. Sanders, D. Lobo, and A. , Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease, Inflammatory Bowel Diseases Gut, vol.1253, pp.1123-1131, 2004.

L. Peyrin-biroulet, P. Deltenre, and N. De-suray, Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials, Clinical Gastroenterology and Hepatology, vol.6, issue.6, pp.644-53, 2008.
DOI : 10.1016/j.cgh.2008.03.014

J. Colombel, W. Sandborn, and P. Rutgeerts, Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn???s Disease: The CHARM Trial, Gastroenterology, vol.132, issue.1, pp.52-65, 2007.
DOI : 10.1053/j.gastro.2006.11.041

S. Hanauer, B. Feagan, and G. Lichtenstein, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, The Lancet, vol.359, issue.9317, pp.1541-1550, 2002.
DOI : 10.1016/S0140-6736(02)08512-4

S. Schreiber, M. Khaliq-kareemi, and I. Lawrance, Maintenance Therapy with Certolizumab Pegol for Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.239-50, 2007.
DOI : 10.1056/NEJMoa062897

L. Peyrin-biroulet, . Dp, C. Stalgis, W. Sandborn, and J. Colombel, Achieving long-term maintenance of remission in Crohn's disease: are all anti-TNF created equal?, Gut, vol.55, p.131, 2006.

P. Allen, H. Lindsay, and T. Tham, How do patients with inflammatory bowel disease want their biological therapy administered?, BMC Gastroenterology, vol.30, issue.3
DOI : 10.1111/j.1365-2036.2009.04033.x

S. Kane and F. Shaya, Medication Non-adherence is Associated with Increased Medical Health Care Costs, Digestive Diseases and Sciences, vol.31, issue.11, pp.1020-1024, 2008.
DOI : 10.1007/s10620-007-9968-0

S. Kane, J. Chao, and P. Mulani, Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn???s disease patients, Advances in Therapy, vol.11, issue.suppl.1, pp.936-982, 2009.
DOI : 10.1111/j.1524-4733.2007.00213.x

S. Kane, D. Huo, and J. Aikens, Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis, The American Journal of Medicine, vol.114, issue.1, pp.39-43, 2003.
DOI : 10.1016/S0002-9343(02)01383-9

S. Kane and L. Dixon, Adherence rates with infliximab therapy in Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.4, issue.7, p.24
DOI : 10.1053/cgh.2003.50025

J. Satsangi, M. Silverberg, and S. Vermeire, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006.
DOI : 10.1136/gut.2005.082909

E. Delong, D. Delong, and D. Clarke-pearson, Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach, Biometrics, vol.44, issue.3, pp.837-882, 1988.
DOI : 10.2307/2531595

G. Plosker and K. Lyseng-williamson, Adalimumab, BioDrugs, vol.20, issue.5, pp.125-157, 2007.
DOI : 10.2165/00063030-200721020-00007

K. Karmiris, G. Paintaud, and M. Noman, Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease, Gastroenterology, vol.137, issue.5
DOI : 10.1053/j.gastro.2009.07.062

B. Borah, X. Huang, and V. Zarotsky, Trends in RA patients??? adherence to subcutaneous anti-TNF therapies and costs, Current Medical Research and Opinion, vol.25, issue.6, p.8, 2009.
DOI : 10.1185/03007990902896386

I. Bernal, E. Domenech, and E. Garcia-planella, Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease, Digestive Diseases and Sciences, vol.5, issue.12, pp.2165-2174, 2006.
DOI : 10.1007/s10620-006-9444-2

T. Moshkovska, M. Stone, and R. Baker, Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis Risk factors for non-adherence to medication in inflammatory bowel disease patients al. Patient nonadherence to medication in inflammatory bowel disease, Inflamm Bowel Dis Aliment Pharmacol Ther Sewitch MJ, Abrahamowicz M Am J Gastroenterol, vol.142798, issue.31, pp.763-8166, 2003.

G. Nguyen, T. Laveist, and M. Harris, Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease, p.24